FDA Approves VYVANSE(TM) (lisdexamfetamine Dimesylate), The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults
BASINGSTOKE, England and PHILADELPHIA, April 23 /PRNewswire/ -- - Within the First Eight Months Since its Introduction in the United States, VYVANSE has Achieved Over One Million Prescriptions - In a Clinical Study With Adults, VYVANSE was Shown to Significantly Improve the Symptoms of ADHD (Inattention, Hyperactivity and Impulsivity)(1)
Source: science20.com
